![ESMO23_Venue_06](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/general-pics/esmo23_venue_06/18324309-1-eng-GB/esmo23_venue_06_i770.jpg)
Tissue agnostic study shows activity of ADCs in solid tumours with HER2 activating mutations
In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types